Cyclopentolate ophthalmic Alternatives Compared
| Cyclopentolate ophthalmic | Methotrexate | Humira (adalimumab) |
|
|---|
| Cyclopentolate ophthalmic | Methotrexate | Humira (adalimumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Uveitis, Pupillary Dilation, Refraction - Assessment. Cyclopentolate ophthalmic may also be used for purposes not listed in this medication guide. |
Prescription only
Methotrexate may be considered for the treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), mycosis fungoides, and certain cancers, such as ALL or... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Cyclopentolate ophthalmic | More about Methotrexate | More about Humira (adalimumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Cyclopentolate ophthalmic has an average rating of 2.0 out of 10 from a total of 3 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 67% reported a negative effect. |
Methotrexate has an average rating of 6.5 out of 10 from a total of 335 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 24% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 698 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Methotrexate side effects |
View all Humira side effects |
|||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Cyclopentolate ophthalmic prices |
View all Methotrexate prices |
View all Humira prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Ak-Pentolate, Cyclogyl, Cylate | Jylamvo, Methotrexate LPF Sodium, Otrexup, Rasuvo, Trexall, Xatmep | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
15 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 17 drugs are known to interact with Cyclopentolate ophthalmic:
|
A total of 722 drugs are known to interact with Methotrexate:
|
A total of 552 drugs are known to interact with Humira:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
December 07, 1953 |
December 31, 2002 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.